Medtronic Acquires CathWorks to Enhance Cardiovascular Care

Medtronic has completed its acquisition of CathWorks, a medical device company known for its innovative FFRangio® System, which uses drug-free and wire-free technology for comprehensive physiological assessment in diagnosing and treating coronary artery disease. Valued at $585 million, this acquisition follows a prior strategic partnership and aims to enhance Medtronic’s interventional cardiology portfolio by providing physicians with improved data-driven insights and patient outcomes.